| 1 |
NCT00101140 |
Withdrawn |
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission |
- Adult Acute Erythroid Leukemia
- Adult Acute Monoblastic and Acute Monocytic Leukemia
- Adult Acute Myeloid Leukemia
|
- Drug: anti-thymocyte globulin
- Drug: fludarabine phosphate
- Drug: thiotepa
- (and 6 more...)
|
Interventional
|
Phase 2 |
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
0 |
All |
18 Years to 59 Years (Adult) |
NCT00101140 |
CDR0000405838
ECOG-E1903 |
|
|
|
|
January 10, 2005 |
October 19, 2017 |
|
|
|
| 2 |
NCT01642121 |
Completed |
Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia |
- Childhood Acute Monoblastic Leukemia (M5a)
- Childhood Acute Monocytic Leukemia (M5b)
- Childhood Acute Myeloblastic Leukemia Without Maturation (M1)
- (and 2 more...)
|
- Other: laboratory biomarker analysis
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case Control
- Time Perspective: Retrospective
|
- Expression of the CD55 marker on CD34+CD38‐ cells
- Presence of the AML1-ETO translocation
|
20 |
All |
up to 30 Years (Child, Adult) |
NCT01642121 |
AAML12B10
NCI-2012-01983 |
|
August 2012 |
May 2016 |
|
July 17, 2012 |
May 19, 2016 |
|
- Children's Oncology Group
Monrovia, California, United States
|
|
| 3 |
NCT01307579 |
Active, not recruiting |
Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy |
- Acute Myeloid Leukemia
- Adult Acute Megakaryoblastic Leukemia
- Adult Acute Monoblastic Leukemia
- (and 30 more...)
|
- Drug: Caspofungin Acetate
- Drug: Fluconazole
- Other: Laboratory Biomarker Analysis
|
Interventional
|
Phase 3 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Time to development of proven or probable IFI, defined according to criteria developed by the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG)
- Time to development of proven or probably invasive aspergillosis (IA), defined according to the criteria developed by the EORTC/MSG
- Time to death due to any cause
- (and 3 more...)
|
575 |
All |
3 Months to 30 Years (Child, Adult) |
NCT01307579 |
ACCL0933
NCI-2011-02640
CDR0000695748
COG-ACCL0933
S12-00316
U10CA095861
UG1CA189955 |
|
April 4, 2011 |
December 31, 2018 |
|
March 3, 2011 |
August 7, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - (and 176 more...)
|
|
| 4 |
NCT01801046 |
Terminated |
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Monoblastic Leukemia (M5a)
- Adult Acute Monocytic Leukemia (M5b)
- (and 24 more...)
|
- Drug: mitoxantrone hydrochloride
- Drug: cytarabine
- Procedure: peripheral blood stem cell transplantation
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 1 |
- University of Southern California
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Induction mortality
- Complete remission rate (complete remission [CR] or incomplete remission [CRi])
- Occurrence of serious infections (grade 4) assessed using National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) v4.0
- (and 5 more...)
|
10 |
All |
Child, Adult, Older Adult |
NCT01801046 |
9L-11-8
NCI-2013-00447 |
|
March 6, 2013 |
July 27, 2017 |
August 20, 2017 |
February 28, 2013 |
March 30, 2018 |
|
- USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
|
|
| 5 |
NCT00666588 |
Completed
Has Results |
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia |
- Adult Acute Monoblastic Leukemia (M5a)
- Adult Acute Monocytic Leukemia (M5b)
- Adult Acute Myeloblastic Leukemia With Maturation (M2)
- (and 19 more...)
|
- Drug: idarubicin
- Drug: cytarabine
- Drug: bortezomib
- (and 2 more...)
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Limiting Toxicity
- Overall Response (Complete Remission [CR] and CR With Partial Recovery [CRp]) During Course 1
- NF-kB Activity by Enzyme-linked Immunosorbent Assay (ELISA)
- (and 3 more...)
|
52 |
All |
1 Year to 21 Years (Child, Adult) |
NCT00666588 |
NCI-2009-00323
U10CA098543
CDR0000594224
COG-AAML07P1 |
|
April 2008 |
December 2012 |
December 2012 |
April 25, 2008 |
May 22, 2018 |
February 6, 2014 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - (and 79 more...)
|
|
| 6 |
NCT00096148 |
Terminated |
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia |
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- (and 21 more...)
|
- Drug: idarubicin
- Drug: cytarabine
- Biological: bevacizumab
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients who remain alive in the first complete remission (CR) 1 year from achievement of CR assessed every 3 weeks for 1 year
- Safety of idarubicin+cytarabine+bevacizumab by AdEERS, CBC and chem.
|
120 |
All |
up to 59 Years (Child, Adult) |
NCT00096148 |
NCI-2012-02627
MDA-2004-0342
N01CM62202
N01CM62204
CDR0000391189 |
|
October 2004 |
November 2006 |
|
November 9, 2004 |
January 24, 2013 |
|
- M D Anderson Cancer Center
Houston, Texas, United States
|
|
| 7 |
NCT00462605 |
Completed
Has Results |
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia |
- Adult Acute Lymphoblastic Leukemia in Remission
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- (and 25 more...)
|
- Drug: entinostat
- Drug: sargramostim
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response (Complete and Partial Response) in Patients With Myeloid Disorders
- Clinical Activity Assessed by Change in Peripheral Blood Counts
- Clinical Activity Assessed by Change in Transfusion Requirements
- (and 2 more...)
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT00462605 |
NCI-2009-00195
J06114
U01CA070095 |
|
April 2007 |
March 2011 |
March 2011 |
April 19, 2007 |
July 18, 2017 |
April 17, 2017 |
- Johns Hopkins University
Baltimore, Maryland, United States
|
|
| 8 |
NCT00101296 |
Completed |
Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Adult Acute Erythroid Leukemia (M6)
- Adult Acute Megakaryoblastic Leukemia (M7)
- (and 16 more...)
|
- Drug: tipifarnib
- Other: pharmacological study
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD defined as the highest dose level in which six patients have been evaluated for toxicity with no more than one patient experiencing dose limiting toxicity (DLT) assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
- Objective tumor response
- Survival
- (and 2 more...)
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT00101296 |
NCI-2012-03078
PHI-47
U01CA062505
CDR0000404151 |
|
October 2004 |
May 2011 |
|
January 10, 2005 |
February 4, 2013 |
|
- City of Hope
Duarte, California, United States
|
|
| 9 |
NCT00027872 |
Completed |
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia |
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- (and 18 more...)
|
- Drug: tipifarnib
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete remission (CR) rate
- Partial remission (PR) rate
- Toxicity rates assessed using NCI CTCAE version 3.0
- (and 2 more...)
|
125 |
All |
65 Years and older (Older Adult) |
NCT00027872 |
NCI-2012-02980
UMGCC 0116
U01CA069854
U01CA070095 |
|
October 2001 |
July 2007 |
January 2009 |
January 27, 2003 |
March 25, 2013 |
|
- Johns Hopkins University
Baltimore, Maryland, United States
|
|
| 10 |
NCT02038153 |
Unknown † |
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant |
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Adult Acute Megakaryoblastic Leukemia
- Adult Acute Monoblastic Leukemia
- (and 14 more...)
|
- Drug: Lenalidomide
- Other: Laboratory Biomarker Analysis
|
Interventional
|
Phase 1
Phase 2 |
- Albert Einstein College of Medicine, Inc.
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Relapse free survival rate
- Overall survival
|
48 |
All |
60 Years to 75 Years (Adult, Older Adult) |
NCT02038153 |
13-08-148
NCI-2013-02493
P30CA013330 |
|
December 2013 |
January 2016 |
January 2017 |
January 16, 2014 |
March 3, 2015 |
|
- Albert Einstein College of Medicine
Bronx, New York, United States - Montefiore Medical Center - Moses Campus
Bronx, New York, United States
|
|
| 11 |
NCT00658814 |
Active, not recruiting
Has Results |
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia |
- Acute Myeloid Leukemia
- Adult Acute Megakaryoblastic Leukemia
- Adult Acute Monoblastic Leukemia
- (and 12 more...)
|
- Drug: Azacitidine
- Drug: Gemtuzumab Ozogamicin
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response
- 30-Day Survival
- Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
- Relapse-free Survival
|
133 |
All |
60 Years and older (Adult, Older Adult) |
NCT00658814 |
NCI-2009-00790
CDR0000593117
SWOG-S0703
S0703
U10CA032102 |
|
December 1, 2008 |
June 1, 2013 |
|
April 15, 2008 |
September 13, 2018 |
January 6, 2014 |
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, United States - Stanford Cancer Institute Palo Alto
Palo Alto, California, United States - University of California Davis Comprehensive Cancer Center
Sacramento, California, United States - (and 175 more...)
|
|
| 12 |
NCT01260714 |
Terminated |
Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia |
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- (and 18 more...)
|
- Drug: Azacitidine
- Drug: Etoposide
- Other: Laboratory Biomarker Analysis
- Drug: Mitoxantrone Hydrochloride
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum-tolerated dose of azacitidine that can be safely combined with mitoxantrone hydrochloride and etoposide chemotherapy
- Changes in DNA methylation
- Changes in gene expression
- (and 4 more...)
|
13 |
All |
60 Years and older (Adult, Older Adult) |
NCT01260714 |
NCI-2011-02559
CDR0000690647
PHL-074
8331
N01CM00032
N01CM62203 |
|
December 2010 |
March 2015 |
June 2015 |
December 15, 2010 |
August 20, 2015 |
|
- Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada - University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
|
|
| 13 |
NCT01627041 |
Active, not recruiting |
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia |
- Acute Myeloid Leukemia
- Adult Acute Basophilic Leukemia
- Adult Acute Monoblastic Leukemia
- (and 8 more...)
|
- Drug: Cytarabine
- Drug: Daunorubicin Hydrochloride
- Drug: Decitabine
- (and 2 more...)
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete remission rate (CR1)
- Complete remission rate (CR1 + CR2)
- Overall survival
- (and 4 more...)
|
180 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01627041 |
NCI-2012-01959
1106011736
CDR0000712322
8854
N01CM62204
P30CA013696 |
|
September 16, 2011 |
October 1, 2022 |
|
June 25, 2012 |
July 17, 2018 |
|
- Lafayette Family Cancer Center-EMMC
Brewer, Maine, United States - Montefiore Medical Center-Weiler Hospital
Bronx, New York, United States - Montefiore Medical Center - Moses Campus
Bronx, New York, United States - (and 6 more...)
|
|
| 14 |
NCT00742625 |
Completed
Has Results |
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia |
- Acute Myeloid Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- (and 12 more...)
|
- Drug: daunorubicin hydrochloride
- Drug: cytarabine
- Drug: bortezomib
|
Interventional
|
Phase 1
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Remission Induction Response
- Participants Experiencing a Dose-limiting Toxicity (DLT) of Bortezomib When Administered in Combination With Intermediate-dose Cytarabine
- Disease-free Survival
- Overall Survival
|
95 |
All |
60 Years to 75 Years (Adult, Older Adult) |
NCT00742625 |
NCI-2009-00443
CDR0000612758
CALGB 10502
CALGB-10502
U10CA031946
P30CA014236 |
|
September 2008 |
July 2010 |
December 2012 |
August 28, 2008 |
September 12, 2014 |
February 5, 2013 |
- Washington Hospital Center
Washington, District of Columbia, United States - Lombardi Comprehensive Cancer Center at Georgetown University
Washington, District of Columbia, United States - Florida Hospital
Orlando, Florida, United States - (and 19 more...)
|
|
| 15 |
NCT01349972 |
Completed
Has Results |
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia |
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 13 more...)
|
- Drug: alvocidib
- Drug: daunorubicin hydrochloride
- Drug: mitoxantrone hydrochloride
- Drug: cytarabine
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response Rate
- Incidence of Toxicities, Characterized by Number of Events by Treatment and Grade
- Disease-free Survival
- (and 3 more...)
|
172 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01349972 |
NCI-2011-02587
JHOC-J1101
CDR0000699421
J1101
8972
U01CA070095
N01CM00100
P30CA006973 |
|
April 2011 |
May 2014 |
May 2014 |
May 9, 2011 |
July 31, 2017 |
June 6, 2017 |
- Mayo Clinic Scottsdale-Phoenix
Scottsdale, Arizona, United States - Moffitt Cancer Center
Tampa, Florida, United States - Blood and Marrow Transplant Group of Georgia
Atlanta, Georgia, United States - (and 8 more...)
|
|
| 16 |
NCT01253447 |
Completed
Has Results |
AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 12 more...)
|
- Drug: Akt inhibitor MK2206
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With a Response of CR, CRp, or PR
- Number of Participants With Treatment-related Non-hematological Toxicity
- Maximum Percentage Change in Apoptosis
|
19 |
All |
18 Years and older (Adult, Older Adult) |
NCT01253447 |
NCI-2010-02186
2010-0243
8731
N01CM00039 |
|
October 2010 |
October 2013 |
April 2014 |
December 3, 2010 |
August 27, 2018 |
January 7, 2015 |
- UT MD Anderson Cancer Center
Houston, Texas, United States - Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 17 |
NCT01521936 |
Terminated |
Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Monoblastic Leukemia (M5a)
- Adult Acute Monocytic Leukemia (M5b)
- (and 11 more...)
|
- Dietary Supplement: cholecalciferol
- Other: pharmacological study
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 2 |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Changes in 25(OH)-D3 levels after supplementation
- Pharmacokinetic parameters
- Safety and toxicity parameters
|
4 |
All |
18 Years and older (Adult, Older Adult) |
NCT01521936 |
I 201311
NCI-2011-03554 |
|
December 2011 |
March 2013 |
June 2015 |
January 31, 2012 |
June 19, 2015 |
|
- Roswell Park Cancer Institute
Buffalo, New York, United States
|
|
| 18 |
NCT01904643 |
Terminated |
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 12 more...)
|
- Drug: lenalidomide
- Drug: mitoxantrone hydrochloride
- Drug: etoposide
- Drug: cytarabine
|
Interventional
|
Phase 1 |
- Stanford University
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of lenalidomide when used in combination with MEC determined by DLT using the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE), version 4.0
- Response rate (complete remission [CR], CR with incomplete blood count recovery [CRi], partial remission [PR] or stable disease [SD]) using LeukemiaNet guidelines
- Response duration
- Early mortality
|
17 |
All |
18 Years and older (Adult, Older Adult) |
NCT01904643 |
HEMAML0024
NCI-2013-01349
27313
P30CA124435 |
|
February 2014 |
May 13, 2015 |
July 18, 2015 |
July 22, 2013 |
May 28, 2018 |
|
- Stanford University, School of Medicine
Stanford, California, United States
|
|
| 19 |
NCT00634244 |
Completed
Has Results |
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 11 more...)
|
- Drug: alvocidib
- Drug: mitoxantrone hydrochloride
- Drug: carboplatin
- (and 4 more...)
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The Rate of Complete Remission (CR+CRi)
- The Rate of Treatment Failure
|
92 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00634244 |
NCI-2009-00520
E1906
U10CA021115 |
|
October 2008 |
September 2014 |
October 2014 |
March 12, 2008 |
July 7, 2015 |
July 7, 2015 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Mayo Clinic in Florida
Jacksonville, Florida, United States - (and 17 more...)
|
|
| 20 |
NCT02030405 |
Terminated
Has Results |
Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 12 more...)
|
|
Interventional
|
Phase 2 |
- Bruno C. Medeiros
- National Cancer Institute (NCI)
- Stanford University
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate
- Overall Survival (OS)
|
4 |
All |
18 Years and older (Adult, Older Adult) |
NCT02030405 |
IRB-28771
NCI-2013-02231
P30CA124435
HEMAML0028 |
|
March 2014 |
November 2015 |
November 2015 |
January 8, 2014 |
March 10, 2017 |
March 10, 2017 |
- Stanford University Cancer Institute
Stanford, California, United States
|
|
| 21 |
NCT01820624 |
Completed |
Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Monoblastic Leukemia (M5a)
- Adult Acute Monocytic Leukemia (M5b)
- (and 11 more...)
|
- Drug: tretinoin
- Drug: lithium carbonate
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 1 |
- Paolo Caimi, MD
- National Cancer Institute (NCI)
- Case Comprehensive Cancer Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of tretinoin when given together with lithium carbonate, defined as the dose level immediately below that at which at least 2/6 subjects experience dose-limiting toxicity (DLT), graded using the NCI CTCAE version 4.0
|
12 |
All |
18 Years and older (Adult, Older Adult) |
NCT01820624 |
CASE3912
NCI-2013-00600 |
|
April 30, 2013 |
October 9, 2015 |
November 13, 2015 |
March 29, 2013 |
April 27, 2017 |
|
- University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
|
| 22 |
NCT02049801 |
Terminated |
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- Adult Acute Monocytic Leukemia (M5b)
- (and 12 more...)
|
- Drug: MEK inhibitor MEK162
- Drug: idarubicin
- Drug: cytarabine
- (and 2 more...)
|
Interventional
|
Phase 1 |
- Bruno C. Medeiros
- National Cancer Institute (NCI)
- Stanford University
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of MEK inhibitor MEK162 in combination with chemotherapy, defined as the dose associated with a dose-limiting toxicity rate of 35% assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03
- Pharmacodynamic analysis of downstream inhibition of RAS signaling following therapy with single-agent MEK inhibitor MEK162
- Complete remission rate, defined as bone marrow biopsy demonstrating < 5% blasts and recovery of peripheral blood counts after induction chemotherapy
- (and 2 more...)
|
1 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02049801 |
IRB-29150
NCI-2014-00169
HEMAML0030 |
|
December 2014 |
February 4, 2015 |
November 1, 2017 |
January 30, 2014 |
December 6, 2017 |
|
- Stanford University, School of Medicine
Stanford, California, United States
|
|
| 23 |
NCT01835288 |
Withdrawn |
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 12 more...)
|
- Drug: arsenic trioxide
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 2 |
- Stanford University
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of complete remission following arsenic trioxide induction
- Median duration of remission
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT01835288 |
IRB-26938
NCI-2013-00767
HEMAML0023 |
|
May 2013 |
May 2015 |
|
April 18, 2013 |
May 21, 2018 |
|
|
|
| 24 |
NCT01831232 |
Completed
Has Results |
Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 16 more...)
|
- Drug: pravastatin sodium
- Drug: idarubicin
- Drug: cytarabine
- Other: laboratory biomarker analysis
|
Interventional
|
Not Applicable |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Good Complete Remission (CR)
- Number of Participants With TRM.
- Progression Free Survival (PFS)
- (and 3 more...)
|
24 |
All |
18 Years to 74 Years (Adult, Older Adult) |
NCT01831232 |
2674.00
NCI-2013-00743
P30CA015704 |
|
May 2013 |
February 2015 |
January 2016 |
April 15, 2013 |
November 17, 2017 |
November 17, 2017 |
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 25 |
NCT02029417 |
Terminated
Has Results |
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia |
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- (and 14 more...)
|
- Drug: cytarabine
- Drug: omacetaxine mepesuccinate
- Drug: decitabine
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 2 |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
- Teva Pharmaceutical Industries, Ltd.
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of the Evaluable Population of Interest Who Experience a Complete Response in the Poor and Good Prognosis Groups
- Frequency of Adverse Events, Graded According to NCI CTCAE v4.0
|
2 |
All |
65 Years and older (Older Adult) |
NCT02029417 |
I 245213
NCI-2013-02425
P30CA016056 |
|
July 2014 |
November 2015 |
December 2015 |
January 7, 2014 |
May 9, 2016 |
May 9, 2016 |
- Roswell Park Cancer Institute
Buffalo, New York, United States
|
|
| 26 |
NCT02085408 |
Active, not recruiting |
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia |
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- (and 14 more...)
|
- Drug: clofarabine
- Drug: daunorubicin hydrochloride
- Other: clinical observation
- (and 5 more...)
|
Interventional
|
Phase 3 |
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Mortality rate
- Induction complete response rates
- (and 4 more...)
|
727 |
All |
60 Years and older (Adult, Older Adult) |
NCT02085408 |
E2906
NCI-2011-01992
CDR0000659585
ECOG-E2906
U10CA021115 |
|
December 28, 2010 |
September 2018 |
|
March 12, 2014 |
December 8, 2017 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Arizona Cancer Center at University Medical Center North
Tucson, Arizona, United States - (and 266 more...)
|
|
| 27 |
NCT01555268 |
Completed |
Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 13 more...)
|
- Biological: trebananib
- Drug: cytarabine
- Other: laboratory biomarker analysis
- Other: pharmacological study
|
Interventional
|
Phase 1 |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
- Amgen
|
Other / NIH / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety of trebananib when administered alone and in combination with low-dose cytarabine measured by number of participants with toxicities according to CTCAE
- PK/PD profile of trebananib when administered alone
- PK/PD profile of trebananib when administered in combination with low-dose cytarabine
- (and 5 more...)
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT01555268 |
I 186010
NCI-2011-02979
P30CA016056 |
|
October 31, 2011 |
September 24, 2013 |
August 3, 2016 |
March 15, 2012 |
February 15, 2017 |
|
- Roswell Park Cancer Institute
Buffalo, New York, United States - University of Rochester
Rochester, New York, United States
|
|
| 28 |
NCT01550185 |
Terminated |
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia |
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- (and 14 more...)
|
- Drug: eltrombopag olamine
- Procedure: standard follow-up care
|
Interventional
|
Phase 1 |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
- GlaxoSmithKline
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD and tolerability of eltrombopag olamine in patients with AML, determined according to incidence of dose-limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4
- Platelet count recovery to >= 100 x 10^9/L when eltrombopag olamine is administered following high dose cytarabine and mitoxantrone for the treatment of AML patients
- Platelet recovery to >= 100 x 10^9/L and platelet response, assessed based on a modified International Working Group Consensus Criteria for hematologic improvement
- (and 2 more...)
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT01550185 |
I 206111
NCI-2012-00215 |
|
May 2012 |
December 2014 |
December 2014 |
March 9, 2012 |
April 6, 2016 |
|
- Emory University, Winship Cancer Institute
Atlanta, Georgia, United States - Roswell Park Cancer Institute
Buffalo, New York, United States
|
|
| 29 |
NCT00407966 |
Completed
Has Results |
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia |
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- (and 14 more...)
|
- Drug: alvocidib
- Drug: cytarabine
- Drug: mitoxantrone hydrochloride
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
45 |
All |
18 Years and older (Adult, Older Adult) |
NCT00407966 |
NCI-2012-02986
U01CA070095
P30CA006973
J0669
7845 |
|
October 2006 |
July 2008 |
November 2009 |
December 5, 2006 |
August 4, 2015 |
February 11, 2013 |
- Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States
|
|
| 30 |
NCT01342887 |
Terminated
Has Results |
Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 12 more...)
|
- Drug: cyclosporine
- Drug: pravastatin sodium
- Drug: mitoxantrone hydrochloride
- (and 2 more...)
|
Interventional
|
Phase 1
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Doses Mitoxantrone Hydrochloride and Etoposide When Combined With Cyclosporine and Pravastatin Sodium
- CR/CRi
- Disease-free Survival of Patients That Achieve CR/CRi
- Frequency and Severity of Regimen-associated Toxicities
|
6 |
All |
18 Years and older (Adult, Older Adult) |
NCT01342887 |
2409.00
NCI-2011-00657 |
|
April 2011 |
March 2012 |
March 2012 |
April 27, 2011 |
July 2, 2017 |
July 2, 2017 |
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 31 |
NCT00093418 |
Completed |
S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 14 more...)
|
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Total response rate, defined as the proportion of patients who achieve CR or PR
|
296 |
All |
70 Years and older (Older Adult) |
NCT00093418 |
NCI-2012-03038
S0432
U10CA032102
CDR0000387957 |
|
September 2004 |
June 2006 |
|
October 8, 2004 |
January 15, 2013 |
|
- Southwest Oncology Group
San Antonio, Texas, United States
|
|
| 32 |
NCT02071901 |
Active, not recruiting |
Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy |
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- (and 16 more...)
|
- Drug: eltrombopag olamine
|
Interventional
|
Phase 2 |
- Case Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Patients with a median platelet count >= 50,000/uL
- Median time needed to reach platelet count >= 50,000 /µL
- Number of days of platelet transfusions
- (and 10 more...)
|
31 |
All |
60 Years and older (Adult, Older Adult) |
NCT02071901 |
CASE4913
NCI-2014-00252
P30CA043703 |
|
August 14, 2014 |
December 2018 |
December 2018 |
February 26, 2014 |
October 15, 2018 |
|
- Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
|
| 33 |
NCT00305773 |
Completed
Has Results |
Vorinostat in Treating Patients With Acute Myeloid Leukemia |
- Adult Acute Erythroid Leukemia (M6)
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- (and 15 more...)
|
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Confirmed Complete Response (CR) Rate
- Time to Progression (TTP)
- Overall Survival (OS)
- Number of Participants With Severe (Grade 3, 4 or 5) Adverse Events
|
37 |
All |
18 Years and older (Adult, Older Adult) |
NCT00305773 |
NCI-2012-01470
CDR0000465213
JHOC-J0557
MAYO-MC0483
JHOC-J0550
NCI-6882
MC0483
6882
N01CM62205
P30CA015083 |
|
January 2006 |
May 2009 |
January 2010 |
March 22, 2006 |
May 19, 2014 |
May 16, 2013 |
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 34 |
NCT00673153 |
Terminated
Has Results |
Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 12 more...)
|
- Drug: gemtuzumab ozogamicin
- Drug: vorinostat
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants Achieving CR or CRi With Induction Therapy (Good-risk Group)
- Number of Participants Alive at Day 30 (Poor-risk Group)
- Relapse-free Survival (Good- and Poor-risk Group)
- (and 2 more...)
|
31 |
All |
60 Years and older (Adult, Older Adult) |
NCT00673153 |
2200.00
NCI-2010-00401 |
|
March 2008 |
August 2010 |
|
May 7, 2008 |
June 1, 2017 |
June 1, 2017 |
- Stanford University
Stanford, California, United States - Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States - Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States - Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 35 |
NCT02144675 |
Completed
Has Results |
Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 14 more...)
|
- Drug: choline magnesium trisalicylate
- Drug: idarubicin
- Drug: cytarabine
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 2 |
- Rutgers, The State University of New Jersey
- Rutgers Cancer Institute of New Jersey
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Inhibition of NF-kB Target Transcripts and/or Inhibition of Drug Efflux in at Least 50% of Patients
|
27 |
All |
18 Years and older (Adult, Older Adult) |
NCT02144675 |
020803
NCI-2012-00516
0220080282
P30CA072720 |
|
January 2009 |
April 26, 2016 |
April 26, 2016 |
May 22, 2014 |
July 24, 2018 |
July 24, 2018 |
- Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
|
|
| 36 |
NCT00352365 |
Completed
Has Results |
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia |
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- (and 14 more...)
|
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response
- Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
- Cytogenetic Abnormalities
- Total Response
|
41 |
All |
60 Years and older (Adult, Older Adult) |
NCT00352365 |
NCI-2009-00785
SWOG-S0605
CDR0000484449
S0605
U10CA032102 |
|
June 2006 |
December 2010 |
July 2011 |
July 14, 2006 |
July 31, 2014 |
July 4, 2013 |
- University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - Shasta Regional Medical Center
Redding, California, United States - Sutter Roseville Medical Center
Roseville, California, United States - (and 51 more...)
|
|
| 37 |
NCT00089388 |
Terminated |
Cilengitide in Treating Patients With Acute Myeloid Leukemia |
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- (and 9 more...)
|
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free survival (DFS)
- Overall survival
- Toxicity of cilengitide graded using the CTC version 3
|
70 |
All |
50 Years and older (Adult, Older Adult) |
NCT00089388 |
NCI-2012-02621
MDA-2003-1007
CDR0000378310 |
|
July 2004 |
June 2006 |
|
August 5, 2004 |
January 24, 2013 |
|
- M D Anderson Cancer Center
Houston, Texas, United States
|
|
| 38 |
NCT01361464 |
Completed
Has Results |
Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia
- Adult Acute Monoblastic Leukemia
- Adult Acute Monocytic Leukemia
- (and 13 more...)
|
- Drug: Tipifarnib
- Other: Laboratory Biomarker Analysis
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Remission (CR) Rate
- Median Overall Survival (OS)
- Median 1-Year Survival Rate
- Number of Participants With Relapse Free Survival
|
21 |
All |
65 Years and older (Older Adult) |
NCT01361464 |
NCI-2011-02589
16572
CDR0000699713
8977
P30CA076292
N01CM00071
U01CA070095
N01CM00100 |
|
May 2011 |
November 2014 |
November 2014 |
May 26, 2011 |
April 8, 2015 |
January 6, 2014 |
- Moffitt Cancer Center
Tampa, Florida, United States - Emory University/Winship Cancer Institute
Atlanta, Georgia, United States - Blood and Marrow Transplant Group of Georgia
Atlanta, Georgia, United States - (and 4 more...)
|
|
| 39 |
NCT01839240 |
Active, not recruiting |
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Monoblastic Leukemia (M5a)
- Adult Acute Monocytic Leukemia (M5b)
- (and 14 more...)
|
- Drug: azacitidine
- Drug: cytarabine
- Drug: mitoxantrone hydrochloride
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 1 |
- University of Chicago
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recommended phase II dose of azacitidine when combined with high-dose cytarabine and mitoxantrone hydrochloride, based on incidence of dose limiting toxicity (DLT) graded according to the National Cancer Institute Common Toxicity Criteria, version 4
- Change in gene expression levels of topoisomerase II and deoxycytidine kinase in leukemic blasts pre-treatment and following therapy with azacitidine will be measured by real-time polymerase chain reaction (RT-PCR)
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT01839240 |
12-0111
NCI-2012-02028 |
|
June 6, 2012 |
September 2018 |
September 2018 |
April 24, 2013 |
January 4, 2018 |
|
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
|
|
| 40 |
NCT00217646 |
Completed |
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia |
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Megakaryoblastic Leukemia
- (and 21 more...)
|
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
|
36 |
All |
18 Years and older (Adult, Older Adult) |
NCT00217646 |
NCI-2009-00081
CDR0000442847
2004-0702
6742
P30CA016672
U01CA062461 |
|
October 2005 |
December 2010 |
|
September 22, 2005 |
April 28, 2015 |
|
- M D Anderson Cancer Center
Houston, Texas, United States
|
|
| 41 |
NCT01822015 |
Active, not recruiting |
Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Monoblastic Leukemia (M5a)
- Adult Acute Monocytic Leukemia (M5b)
- (and 11 more...)
|
- Drug: Sirolimus
- Drug: Idarubicin
- Drug: Cytarabine
|
Interventional
|
Early Phase 1 |
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Thomas Jefferson University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in measurement of mTOR activation paired with mTOR target inhibition
- Overall survival
- Progression free survival
- (and 2 more...)
|
55 |
All |
18 Years and older (Adult, Older Adult) |
NCT01822015 |
12D.588
2012-55 |
|
March 15, 2013 |
December 2019 |
June 2020 |
April 1, 2013 |
April 24, 2018 |
|
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
|
| 42 |
NCT00369317 |
Completed
Has Results |
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes |
- Childhood Acute Basophilic Leukemia
- Childhood Acute Eosinophilic Leukemia
- Childhood Acute Erythroleukemia (M6)
- (and 12 more...)
|
- Drug: asparaginase
- Drug: daunorubicin hydrochloride
- Drug: cytarabine
- (and 3 more...)
|
Interventional
|
Phase 3 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event-free Survival (EFS) at 3 Years
- Overall Survival (OS) at 3 Years
- Induction Remission Rate
- (and 6 more...)
|
205 |
All |
up to 4 Years (Child) |
NCT00369317 |
AAML0431
NCI-2009-00318
CDR0000492776
COG-AAML0431
U10CA098543 |
|
March 2007 |
December 2013 |
December 2013 |
August 29, 2006 |
August 14, 2017 |
January 13, 2015 |
- Phoenix Childrens Hospital
Phoenix, Arizona, United States - Southern California Permanente Medical Group
Downey, California, United States - Miller Children's Hospital
Long Beach, California, United States - (and 94 more...)
|
|
| 43 |
NCT00045435 |
Active, not recruiting
Has Results |
Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission |
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- (and 14 more...)
|
- Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Drug: fludarabine phosphate
- Radiation: total-body irradiation
- (and 3 more...)
|
Interventional
|
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free Survival-incidence of Survival Without Relapse
- Nonrelapse Mortality (NRM)-Incidence of Nonrelapse Death
- Overall Survival
- (and 3 more...)
|
17 |
All |
55 Years and older (Adult, Older Adult) |
NCT00045435 |
1654.00
NCI-2011-01307 |
|
April 2002 |
June 2009 |
|
January 27, 2003 |
June 20, 2018 |
March 16, 2017 |
- OHSU Cancer Institute
Portland, Oregon, United States - Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 44 |
NCT00096122 |
Completed
Has Results |
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia |
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- (and 20 more...)
|
- Drug: cytarabine
- Drug: idarubicin
- Drug: tipifarnib
|
Interventional
|
Phase 1
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Complete Response
|
95 |
All |
15 Years to 70 Years (Child, Adult, Older Adult) |
NCT00096122 |
NCI-2012-02862
2003-0563
6625
N01CM62202 |
|
September 2004 |
September 2006 |
February 2010 |
November 9, 2004 |
May 26, 2014 |
July 15, 2011 |
- M D Anderson Cancer Center
Houston, Texas, United States
|
|
| 45 |
NCT00098423 |
Completed |
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes |
- Accelerated Phase Chronic Myelogenous Leukemia
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- (and 23 more...)
|
- Drug: tanespimycin
- Drug: cytarabine
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tolerability of tanespimycin with cytarabine in patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, or high-grade myelodysplastic syndromes
- Clinical response
- Plasma level of tanespimycin
- Effects on client proteins
|
42 |
All |
18 Years and older (Adult, Older Adult) |
NCT00098423 |
NCI-2009-00056
NCI-6383
CDR0000401509
MC0313
6383
U01CA070095
U01CA069912 |
|
November 2004 |
May 2009 |
|
December 8, 2004 |
September 30, 2013 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 46 |
NCT00795002 |
Completed
Has Results |
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia |
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- (and 14 more...)
|
- Drug: alvocidib
- Drug: mitoxantrone hydrochloride
- Drug: cytarabine
- (and 2 more...)
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response
- Number of Participants Experiencing Death From Any Cause Within 60 Days of Starting FLAM
- Disease-free Survival
|
78 |
All |
18 Years and older (Adult, Older Adult) |
NCT00795002 |
NCI-2009-00298
CDR0000625222
J0856
8237
P30CA006973
U01CA070095 |
|
November 2008 |
November 2010 |
September 2012 |
November 21, 2008 |
August 7, 2018 |
December 5, 2013 |
- Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States - Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 47 |
NCT01127009 |
Completed |
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 12 more...)
|
- Drug: bortezomib
- Drug: mitoxantrone hydrochloride
- Drug: etoposide
- (and 2 more...)
|
Interventional
|
Phase 1 |
- Case Comprehensive Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of bortezomib
- Non-dose limiting toxicities
- CR/ CRp rate
- CD74 antigen expression
|
3 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01127009 |
CASE4909
NCI-2010-01203 |
|
July 2010 |
May 2014 |
May 2014 |
May 20, 2010 |
August 13, 2015 |
|
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
|
| 48 |
NCT00112853 |
Completed |
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 12 more...)
|
- Drug: tipifarnib
- Drug: etoposide
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients who experience dose limiting toxicities (DLT), based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0
- Clinical response in terms of optimal dose combination for further study
- Clinical tolerance in terms of additive or synergistic non-hematologic toxicities grade 2 or greater
- Surrogates of response in terms of cell cycle progression and apoptosis, deoxyribonucleic acid (DNA) damage, and results of in vitro model studies (using pre-post assessments).
|
100 |
All |
70 Years and older (Older Adult) |
NCT00112853 |
NCI-2012-03160
J04110
N01CM62204
U01CA070095 |
|
March 2005 |
May 2009 |
|
June 3, 2005 |
January 9, 2013 |
|
- Johns Hopkins University
Baltimore, Maryland, United States
|
|
| 49 |
NCT00602771 |
Completed
Has Results |
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia |
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- (and 14 more...)
|
- Drug: tipifarnib
- Drug: etoposide
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
84 |
All |
70 Years and older (Older Adult) |
NCT00602771 |
NCI-2009-00278
CDR0000584212
J07109
8077
N01CM62204
P30CA006973
U01CA070095 |
|
January 2008 |
October 2011 |
October 2011 |
January 28, 2008 |
October 9, 2014 |
May 26, 2014 |
- Blood and Marrow Transplant Group of Georgia
Atlanta, Georgia, United States - Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States - University of Michigan
Ann Arbor, Michigan, United States - (and 2 more...)
|
|
| 50 |
NCT01076569 |
Completed |
Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia |
- Childhood Acute Basophilic Leukemia
- Childhood Acute Eosinophilic Leukemia
- Childhood Acute Erythroleukemia (M6)
- (and 9 more...)
|
- Other: laboratory biomarker analysis
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case Control
- Time Perspective: Retrospective
|
- Detailed molecular map of pediatric high-risk acute myeloid leukemia
- Mutations in identifying novel changes associated with pediatric AML
- Expression profile in identifying novel changes associated with pediatric AML
- (and 5 more...)
|
250 |
All |
up to 21 Years (Child, Adult) |
NCT01076569 |
AAML10B14
NCI-2011-02212
COG-AAML10B14
U10CA098543 |
|
March 2010 |
May 2016 |
May 2016 |
February 26, 2010 |
May 19, 2016 |
|
- Children's Oncology Group
Monrovia, California, United States
|
|
| 51 |
NCT00006363 |
Completed |
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia |
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Erythroid Leukemia (M6)
- (and 30 more...)
|
- Drug: cytarabine
- Drug: daunorubicin hydrochloride
- Drug: etoposide
- (and 8 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free survival
- Overall survival
- Estimates of disease-free survival curves
- (and 2 more...)
|
720 |
All |
15 Years to 59 Years (Child, Adult) |
NCT00006363 |
NCI-2012-02824
CALGB-19808
U10CA031946 |
|
November 2000 |
June 2005 |
|
January 27, 2003 |
June 4, 2013 |
|
- Cancer and Leukemia Group B
Chicago, Illinois, United States
|
|
| 52 |
NCT01870596 |
Completed
Has Results |
Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia
- Adult Acute Monoblastic Leukemia
- Adult Acute Monocytic Leukemia
- (and 12 more...)
|
- Drug: Cytarabine
- Drug: CHK1 Inhibitor SCH 900776
- Other: Laboratory Biomarker Analysis
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate(CR/CRi) Rate
|
32 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01870596 |
NCI-2013-01097
J1319
9362
U01CA070095
P30CA006973 |
|
May 2013 |
December 2014 |
December 2014 |
June 6, 2013 |
September 1, 2016 |
September 1, 2016 |
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Blood and Marrow Transplant Group of Georgia
Atlanta, Georgia, United States - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital
Baltimore, Maryland, United States - (and 2 more...)
|
|
| 53 |
NCT01235572 |
Completed |
Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 14 more...)
|
- Procedure: standard follow-up care
- Other: medical chart review
- Procedure: quality-of-life assessment
|
Interventional
|
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Proportion of early deaths among patients who are discharged after completion of induction or salvage chemotherapy
|
200 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01235572 |
2449.00
NCI-2012-03028
P30CA015704 |
|
December 2010 |
July 2014 |
July 2014 |
November 5, 2010 |
February 6, 2015 |
|
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 54 |
NCT01168219 |
Active, not recruiting
Has Results |
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia |
- Acute Myeloid Leukemia
- Adult Acute Megakaryoblastic Leukemia
- Adult Acute Monoblastic Leukemia
- (and 20 more...)
|
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
- Biological: Anti-Thymocyte Globulin
- Drug: Azacitidine
- (and 6 more...)
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free Survival
- Overall Survival (OS)
- Treatment Related Mortality (TRM)
|
68 |
All |
18 Years to 74 Years (Adult, Older Adult) |
NCT01168219 |
NCI-2011-02053
CALGB-100801
CDR0000681025
CALGB 100801
U10CA180821
U10CA031946 |
|
July 15, 2010 |
November 15, 2015 |
November 15, 2018 |
July 23, 2010 |
July 10, 2018 |
April 3, 2018 |
- Beebe Medical Center
Lewes, Delaware, United States - Christiana Care Health System-Christiana Hospital
Newark, Delaware, United States - Florida Hospital Orlando
Orlando, Florida, United States - (and 12 more...)
|
|
| 55 |
NCT00002798 |
Completed |
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome |
- Childhood Acute Erythroleukemia (M6)
- Childhood Acute Megakaryocytic Leukemia (M7)
- Childhood Acute Monoblastic Leukemia (M5a)
- (and 13 more...)
|
- Drug: asparaginase
- Drug: daunorubicin hydrochloride
- Drug: fludarabine phosphate
- (and 13 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportions of patients achieving remission rate during induction therapy
- Proportion of patients dying or with residual disease during induction therapy
- Time to marrow recovery (induction phase)
- (and 8 more...)
|
880 |
All |
up to 21 Years (Child, Adult) |
NCT00002798 |
NCI-2012-01834
2961
U10CA098543
CDR0000064883 |
|
August 1996 |
September 2006 |
|
January 27, 2003 |
January 16, 2013 |
|
- Children's Oncology Group
Arcadia, California, United States
|
|
| 56 |
NCT01146210 |
Completed |
Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia |
- Childhood Acute Erythroleukemia (M6)
- Childhood Acute Megakaryocytic Leukemia (M7)
- Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)
- (and 15 more...)
|
- Other: laboratory biomarker analysis
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- Identification of children at high risk of having Fanconi anemia
- Identification of Fanconi anemia patients
|
20 |
All |
up to 21 Years (Child, Adult) |
NCT01146210 |
AAML10B2
NCI-2011-02219
COG-AAML10B2
CDR0000671437 |
|
May 2009 |
May 2016 |
May 2016 |
June 17, 2010 |
May 17, 2016 |
|
- Children's Oncology Group
Monrovia, California, United States
|
|
| 57 |
NCT01031368 |
Completed |
Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 15 more...)
|
- Drug: cytarabine
- Drug: clofarabine
- Drug: filgrastim
- (and 2 more...)
|
Interventional
|
Phase 1 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Grade 3 or greater infusion toxicity, as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
- Treatment-related mortality
- Platelet refractoriness in the presence of alloimmunization
- (and 2 more...)
|
29 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01031368 |
2335.00
NCI-2009-01333 |
|
December 2009 |
September 2012 |
|
December 14, 2009 |
August 15, 2014 |
|
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 58 |
NCT01159301 |
Terminated |
Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia |
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- (and 16 more...)
|
- Drug: entinostat
- Drug: sorafenib tosylate
- Other: pharmacological study
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum-tolerated dose as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Safety as assessed by the NCI CTCAE version 4.0
- Pharmacokinetic profile of sorafenib tosylate
- (and 2 more...)
|
44 |
All |
18 Years and older (Adult, Older Adult) |
NCT01159301 |
NCI-2011-01435
CDR0000675600
I-165409
8272 |
|
June 2010 |
September 2013 |
|
July 9, 2010 |
September 19, 2013 |
|
- Roswell Park Cancer Institute
Buffalo, New York, United States
|
|
| 59 |
NCT01849276 |
Active, not recruiting |
Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 14 more...)
|
- Drug: metformin hydrochloride
- Drug: cytarabine
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate toxicity by assessing the adverse events of metformin and cytarabine
- Study treatment dose toxicity will be evaluated by measurement of adverse events experienced while on treatment
- Remission rate
- (and 3 more...)
|
2 |
All |
18 Years and older (Adult, Older Adult) |
NCT01849276 |
NU 11H03
NCI-2011-01084
STU00048047 |
|
July 2013 |
July 2018 |
August 2019 |
May 8, 2013 |
September 13, 2017 |
|
- Northwestern University
Chicago, Illinois, United States
|
|
| 60 |
NCT00003190 |
Completed |
Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 12 more...)
|
- Drug: cytarabine
- Drug: daunorubicin hydrochloride
- Drug: etoposide
- Drug: valspodar
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free survival
- Overall survival
|
640 |
All |
60 Years and older (Adult, Older Adult) |
NCT00003190 |
NCI-2012-02793
CALGB-9720
U10CA031946 |
|
January 1998 |
August 2002 |
|
October 28, 2003 |
June 4, 2013 |
|
- Cancer and Leukemia Group B
Chicago, Illinois, United States
|
|
| 61 |
NCT00101231 |
Terminated |
Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia |
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- (and 16 more...)
|
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximal tolerable dose of flavopiridol
|
88 |
All |
1 Year and older (Child, Adult, Older Adult) |
NCT00101231 |
NCI-2012-01461
OSU 0479
NCI-6947
OSU-2004C0085
OSU-0479
CDR0000404374
U01CA076576 |
|
October 2004 |
November 2012 |
|
January 10, 2005 |
June 4, 2013 |
|
- Ohio State University Medical Center
Columbus, Ohio, United States
|
|
| 62 |
NCT00383474 |
Completed |
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase |
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Megakaryoblastic Leukemia
- (and 18 more...)
|
- Drug: Bortezomib
- Other: Laboratory Biomarker Analysis
- Drug: Tipifarnib
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose-limiting toxicity and maximum tolerated dose of tipifarnib and bortezomib
- Changes in apoptotic protein expression (Bim, Bax, AKT)
- Clinical efficacy (response rate) evaluated using the revised International Working Group Criteria (IWG) for AML
- Farnesytransferase and proteasome inhibition in peripheral blood mononuclear cells
|
35 |
All |
18 Years and older (Adult, Older Adult) |
NCT00383474 |
NCI-2009-00147
CDR0000502258
MCC-14796
7306
N01CM62208
P30CA076292 |
|
August 2006 |
June 2012 |
June 2012 |
October 3, 2006 |
April 15, 2015 |
|
- Moffitt Cancer Center
Tampa, Florida, United States
|
|
| 63 |
NCT00098826 |
Completed |
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes |
- Acute Undifferentiated Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- (and 24 more...)
|
- Drug: ispinesib
- Other: laboratory biomarker analysis
- Other: pharmacological study
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) of ispinesib, based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0
- Pharmacokinetics of ispinesib in terms of total systemic clearance, peak concentration, area under the curve (AUC), and half-lives
- Treatment-related and dose-limiting toxicities of ispinesib, based on the NCI CTCAE v3.0
- (and 4 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT00098826 |
NCI-2012-03127
CASE 3904
U01CA062502
U01CA062505 |
|
December 2004 |
May 2008 |
|
December 9, 2004 |
January 11, 2013 |
|
- Case Western Reserve University
Cleveland, Ohio, United States
|
|
| 64 |
NCT00301938 |
Completed |
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes |
- Accelerated Phase Chronic Myelogenous Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- (and 23 more...)
|
- Drug: 7-hydroxystaurosporine
- Drug: perifosine
- Other: pharmacological study
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of 7-hydroxystaurosporine administered after perifosine
- Response rate, determined by improvement of blast cell count, degree of marrow infiltration by tumor cells, and improvement in peripheral blood count
- Progression free survival
- (and 3 more...)
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT00301938 |
NCI-2009-00149
MSGCC-0507
NCI-7311
MSGCC-H-27229-0507
CDR0000465368
GCC 0507
7311 |
|
December 2005 |
May 2012 |
|
March 13, 2006 |
September 30, 2013 |
|
- University of Maryland Greenebaum Cancer Center
Baltimore, Maryland, United States
|
|
| 65 |
NCT00093470 |
Completed
Has Results |
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission |
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Adult Acute Megakaryoblastic Leukemia
- Adult Acute Monocytic Leukemia
- (and 14 more...)
|
- Procedure: Clinical Observation
- Drug: Tipifarnib
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free Survival
- Overall Survival
|
144 |
All |
18 Years and older (Adult, Older Adult) |
NCT00093470 |
NCI-2009-00535
E2902
U10CA180820
U10CA021115 |
|
August 18, 2004 |
February 20, 2015 |
|
October 8, 2004 |
April 19, 2018 |
November 10, 2015 |
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - (and 338 more...)
|
|
| 66 |
NCT02019069 |
Recruiting |
CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome |
- Adult Acute Erythroid Leukemia (M6)
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- (and 13 more...)
|
- Drug: liposomal cytarabine-daunorubicin CPX-351
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 2 |
- Rondeep Brar
- National Cancer Institute (NCI)
- Stanford University
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of mortality assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Incidence of mortality assessed using the CTCAE version 4.0
- Incidence of serious adverse events as assessed by CTCAE version 4.0
- (and 5 more...)
|
33 |
All |
60 Years and older (Adult, Older Adult) |
NCT02019069 |
HEM0036
NCI-2013-01982
4593
P30CA124435
28524 |
|
February 2014 |
July 2019 |
December 2019 |
December 24, 2013 |
May 14, 2018 |
|
- Stanford University, School of Medicine
Stanford, California, United States
|
|
| 67 |
NCT00895934 |
Completed
Has Results |
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 11 more...)
|
- Drug: vorinostat
- Drug: gemtuzumab ozogamicin
- Drug: azacitidine
|
Interventional
|
Phase 1
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose-limiting Toxicity and Maximum Tolerated Dose of Vorinostat (Phase I)
- Efficacy Defined as Best Response Achieved During Study Treatment Measured by Complete Remission (CR) Rate
- Relapse-free Survival (RFS)
|
53 |
All |
50 Years and older (Adult, Older Adult) |
NCT00895934 |
NCI-2012-01147
IR-6921
CDR0000642213
2288.00
8297
P30CA015704 |
|
May 2009 |
July 2013 |
September 2013 |
May 8, 2009 |
February 6, 2015 |
February 6, 2015 |
- Stanford University Hospitals and Clinics
Stanford, California, United States - Harrison HealthPartners Hematology and Oncology-Bremerton
Bremerton, Washington, United States - Fred Hutchinson Cancer Research Center
Seattle, Washington, United States - University of Washington Medical Center
Seattle, Washington, United States
|
|
| 68 |
NCT00131989 |
Completed |
Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia |
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- (and 14 more...)
|
- Drug: sorafenib tosylate
- Other: pharmacological study
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- DLT defined as non-hematologic > grade 3 or hematologic grade 4 marrow aplasia > 28 days (without leukemia clearance) as assessed by NCI-CTC version 3.0
- MDT based on the incidence of DTL as assessed by NCI-CTC version 3.0
- Response (CR and/or PR)
- (and 3 more...)
|
48 |
All |
18 Years and older (Adult, Older Adult) |
NCT00131989 |
NCI-2012-03154
J-0509
U01CA070095 |
|
June 2005 |
April 2007 |
|
August 19, 2005 |
January 9, 2013 |
|
- Johns Hopkins University
Baltimore, Maryland, United States
|
|
| 69 |
NCT02105116 |
Terminated
Has Results |
AML Therapy With Irradiated Allogeneic Cells |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 13 more...)
|
- Drug: fludarabine phosphate
- Drug: cytarabine
- Biological: donor lymphocytes
- (and 2 more...)
|
Interventional
|
Not Applicable |
- Rutgers, The State University of New Jersey
- National Cancer Institute (NCI)
- Rutgers Cancer Institute of New Jersey
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Adverse Events Related to Experimental Therapy
- Response Rate, Determined by Allogeneic Cell Therapy-related Mortality
- Response Rate, Determined by Duration of Complete Remission
- Progression Free Survival Probability for CR
|
6 |
All |
18 Years and older (Adult, Older Adult) |
NCT02105116 |
021208
NCI-2013-02408
Pro2013002693
P30CA072720 |
|
February 2014 |
December 16, 2015 |
December 16, 2015 |
April 7, 2014 |
July 25, 2018 |
July 25, 2018 |
- Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
|
|
| 70 |
NCT01872819 |
Completed
Has Results |
Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 16 more...)
|
- Other: antitumor drug screening assay
- Drug: chemotherapy
- Biological: biological therapy
|
Interventional
|
Not Applicable |
- University of Washington
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Achievability of Performing Individualized Drug Screening and Initiating Therapy Based on the Results of the Drug Screen for Poor Risk Patients With Relapsed or Refractory AML
- Rate of Complete Response, Defined by Criteria of Cheson et al.
|
16 |
All |
18 Years and older (Adult, Older Adult) |
NCT01872819 |
8003
NCI-2013-01070
P30CA015704 |
|
August 2, 2013 |
November 2014 |
November 17, 2014 |
June 7, 2013 |
July 11, 2018 |
April 17, 2017 |
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 71 |
NCT01407757 |
Completed |
Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531 |
|
- Genetic: DNA analysis
- Genetic: gene expression analysis
- Other: laboratory biomarker analysis
- Other: pharmacogenomic studies
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- Genetic changes in CD33 impact outcome of gemtuzumab ozogamicin-based therapy
|
1000 |
All |
up to 29 Years (Child, Adult) |
NCT01407757 |
AAML11B10
COG-AAML11B10
NCI-2011-03802 |
|
July 2011 |
May 2016 |
|
August 2, 2011 |
May 19, 2016 |
|
|
|
| 72 |
NCT00372593 |
Completed
Has Results |
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia |
|
- Drug: asparaginase
- Drug: cytarabine
- Drug: daunorubicin hydrochloride
- (and 3 more...)
|
Interventional
|
Phase 3 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event-free Survival at 3 Years
- Overall Survival at 3 Years
- Remission Induction Rate After 2 Courses of Induction Therapy
- (and 4 more...)
|
1070 |
All |
up to 29 Years (Child, Adult) |
NCT00372593 |
AAML0531
COG-AAML0531
CDR0000487497 |
|
August 2006 |
August 2013 |
August 2013 |
September 7, 2006 |
April 28, 2017 |
January 13, 2015 |
- UAB Comprehensive Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Banner Desert Medical Center
Mesa, Arizona, United States - (and 195 more...)
|
|
| 73 |
NCT01020734 |
Completed |
Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission |
|
- Biological: anti-thymocyte globulin
- Drug: busulfan
- Drug: cyclophosphamide
- (and 4 more...)
|
Interventional
|
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy of the treatment measured in terms of frequency of relapse and duration of remission
- Engraftment
- Acute and chronic graft-versus-host disease
- (and 2 more...)
|
263 |
All |
15 Years to 75 Years (Child, Adult, Older Adult) |
NCT01020734 |
CDR0000659891
AMC-UUCM-2009-0579 |
|
May 2011 |
July 2015 |
July 2015 |
November 25, 2009 |
December 31, 2015 |
|
- Inje University - Haeundae Paik Hospital
Busan, Korea, Republic of - Asan Medical Center - University of Ulsan College of Medicine
Seoul, Korea, Republic of
|
|
| 74 |
NCT00540956 |
Completed |
Natural Killer Cells in Older Patients With Acute Myeloid Leukemia |
|
- Drug: cytarabine
- Other: laboratory biomarker analysis
|
Interventional
|
Not Applicable |
- Institut Paoli-Calmettes
- National Cancer Institute (NCI)
|
Other |
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evolution of functional natural killer (NK) cells after chemotherapy
- Kinetics of NK cells
- Activation markers of NK cells
|
40 |
All |
65 Years and older (Older Adult) |
NCT00540956 |
CDR0000564106
IPC-LAM-NK
INCA-RECF0429
IPC-2006/002 |
|
November 2006 |
May 2011 |
|
October 8, 2007 |
May 16, 2011 |
|
- Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes
Marseille, France
|
|
| 75 |
NCT01247584 |
Completed |
Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia |
|
- Genetic: DNA analysis
- Genetic: mutation analysis
- Genetic: polymerase chain reaction
- Other: laboratory biomarker analysis
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- Frequency of mutations
- Relapse-free survival
- Overall survival
- Difference in telomere length
|
234 |
All |
up to 21 Years (Child, Adult) |
NCT01247584 |
AAML11B2
COG-AAML11B2
NCI-2011-02846 |
|
November 2010 |
May 2016 |
|
November 24, 2010 |
May 19, 2016 |
|
|
|
| 76 |
NCT01385150 |
Completed |
Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia |
|
- Genetic: mutation analysis
- Genetic: protein analysis
- Other: laboratory biomarker analysis
- (and 2 more...)
|
Observational
|
|
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Other
- Time Perspective: Retrospective
|
- Absence of serum 2HG in all samples without an IDH mutation
- Relationship between 2HG level and survival outcomes
|
220 |
All |
17 Years to 60 Years (Child, Adult) |
NCT01385150 |
CDR0000702952
ECOG-E1900T8 |
|
January 3, 2012 |
February 3, 2012 |
February 3, 2012 |
June 29, 2011 |
May 19, 2017 |
|
|
|
| 77 |
NCT01059734 |
Completed |
S9031-S9126-S9333-S9500-B Biomarker Expression in Patients With Acute Myeloid Leukemia |
|
- Genetic: DNA analysis
- Genetic: RNA analysis
- Genetic: mutation analysis
- (and 3 more...)
|
Observational
|
|
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Time Perspective: Retrospective
|
- Distribution of topoisomerase 2 (TOP2) expression and single nucleotide polymorphisms
- Distributions of mutations in TOP2 phosphorylation sites
- Correlation of TOP2 expression with complete remission rates, relapse-free survival, and overall survival
- Variation of TOP2 expression and mutations in TOP2 phosphorylation sites among patients and disease characteristics
|
357 |
All |
18 Years and older (Adult, Older Adult) |
NCT01059734 |
S9031-S9126-S9333-S9500-B
U10CA032102 |
|
June 2010 |
June 2012 |
June 2012 |
February 1, 2010 |
March 6, 2015 |
|
|
|
| 78 |
NCT00006223 |
Completed |
flt3L in Treating Patients With Acute Myeloid Leukemia |
|
- Biological: recombinant flt3 ligand
|
Interventional
|
Phase 3 |
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
- Cancer and Leukemia Group B
- Southwest Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
|
All |
18 Years and older (Adult, Older Adult) |
NCT00006223 |
CDR0000068143
ECOG-2998
CALGB-19903
SWOG-E2998 |
|
July 2000 |
|
January 2007 |
September 3, 2003 |
June 24, 2013 |
|
- Veterans Affairs Medical Center - Birmingham
Birmingham, Alabama, United States - University of California San Diego Cancer Center
La Jolla, California, United States - Veterans Affairs Medical Center - San Francisco
San Francisco, California, United States - (and 44 more...)
|
|
| 79 |
NCT00898456 |
Active, not recruiting |
Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia |
|
- Genetic: gene expression analysis
- Genetic: molecular genetic technique
- Genetic: polymorphism analysis
- (and 2 more...)
|
Observational
|
|
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Correlation of common single nucleotide polymorphisms (SNPs) and haplotypes of the 3 multidrug resistance genes (P-glycoprotein [Pgp], multidrug resistance-associated protein (MRP-1) and breast cancer resistance protein [BCRP]) with treatment outcome
- Effect of ATP-binding cassette (ABC) B1, ABCC1, and ABCG2 polymorphisms on treatment outcome
- Association of ABCB1, ABCC1, and ABCG2 polymorphisms and haplotypes with Pgp, MRP-1, and BCRP function and expression in pre-treatment blasts
- (and 2 more...)
|
600 |
All |
15 Years and older (Child, Adult, Older Adult) |
NCT00898456 |
CALGB-20501
U10CA031946
U10CA180821
CDR0000514506 |
|
October 2006 |
January 2100 |
|
May 12, 2009 |
August 8, 2017 |
|
- Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, United States
|
|
| 80 |
NCT00814164 |
Terminated
Has Results |
Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia |
|
- Drug: clofarabine
- Drug: daunorubicin hydrochloride
- Genetic: cytogenetic analysis
- (and 3 more...)
|
Interventional
|
Phase 2 |
- Roswell Park Cancer Institute
- Genzyme, a Sanofi Company
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Remission (CR)
- Disease-free Survival
- Overall Survival
- (and 5 more...)
|
21 |
All |
60 Years to 120 Years (Adult, Older Adult) |
NCT00814164 |
CDR0000630678
RPCI-I-132208 |
|
December 2008 |
June 2013 |
August 2013 |
December 24, 2008 |
August 17, 2016 |
August 17, 2016 |
- Roswell Park Cancer Institute
Buffalo, New York, United States
|
|
| 81 |
NCT01154439 |
Active, not recruiting |
Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia |
|
- Drug: cytarabine
- Drug: etoposide
- Drug: everolimus
- (and 2 more...)
|
Interventional
|
Phase 1 |
- Gruppo Italiano Malattie EMatologiche dell'Adulto
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum-tolerated dose of everolimus
- Safety
- Complete remission rate
|
18 |
All |
61 Years to 75 Years (Adult, Older Adult) |
NCT01154439 |
AML1208
GIMEMA-AML1208
2008-007666-28 |
AML1208 |
October 2010 |
May 2013 |
March 2018 |
June 30, 2010 |
February 21, 2018 |
|
- Ematologia con trapianto- AOU Policlinico Consorziale di Bari
Bari, Italy - Azienda Ospedaliera Universitaria - Università degli Studi di Napoli "Federico II" - Facoltà di Medicina e Chirurgia
Napoli, Italy - Università La Sapienza
Roma, Italy - (and 2 more...)
|
|
| 82 |
NCT00898092 |
Active, not recruiting |
Genetics Study of Tissue Collected From Patients With Acute Myeloid Leukemia |
|
- Genetic: microarray analysis
- Genetic: molecular genetic technique
- Genetic: mutation analysis
- (and 3 more...)
|
Observational
|
|
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- Prognostic stratification of patients through BAALC and ERG overexpression and microarray gene-expression signatures
- Differential microRNA expression
- Relative contribution of genetic markers in predicting clinical outcome
|
735 |
All |
15 Years to 59 Years (Child, Adult) |
NCT00898092 |
CALGB-20502
U10CA031946
U10CA180821
CDR0000491133 |
|
May 2006 |
December 2012 |
|
May 12, 2009 |
August 8, 2017 |
|
- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
|
|
| 83 |
NCT00775593 |
Completed
Has Results |
Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia |
|
- Drug: clofarabine
- Drug: temsirolimus
|
Interventional
|
Phase 2 |
- Gruppo Italiano Malattie EMatologiche dell'Adulto
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response Rate
- Number of Serious Adverse Events Within 2 Years
- Duration of Response
- Duration of Survival
|
60 |
All |
60 Years and older (Adult, Older Adult) |
NCT00775593 |
AML1107
GIMEMA-AML-1107
EUDRACT-2007-005374-31 |
AML1107 |
December 2008 |
June 2012 |
October 23, 2013 |
October 20, 2008 |
November 9, 2017 |
March 23, 2015 |
- Azienda ospedaliera Nuovo ospedale "Torrette"
Ancona, Italy - Azienda Ospedaliero-Universitaria Policlinico Consorziale
Bari, Italy - Azienda Ospedaliera Di Bologna Policlinico S. Orsola - Malpighi
Bologna, Italy - (and 16 more...)
|
|
| 84 |
NCT00268242 |
Terminated
Has Results |
Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia |
|
- Drug: Gemcitabine Hydrochloride
- Drug: Mitoxantrone Hydrochloride
|
Interventional
|
Phase 2 |
- The Cleveland Clinic
- National Cancer Institute (NCI)
- Duke University
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response Rate
- Duration of the First Complete Response
- Disease-free and Overall Survival
- (and 3 more...)
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT00268242 |
CASE-CCF-7725
P30CA043703 |
|
January 2006 |
August 2010 |
July 2011 |
December 22, 2005 |
February 22, 2018 |
October 5, 2015 |
- Duke Comprehensive Cancer Center
Durham, North Carolina, United States - Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States
|
|
| 85 |
NCT00544999 |
Unknown † |
Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia |
|
- Drug: cytarabine
- Drug: daunorubicin hydrochloride
- Drug: everolimus
- (and 2 more...)
|
Interventional
|
Phase 1 |
- Institut de Recherche Clinique sur les Cancers et le Sang
- National Cancer Institute (NCI)
|
Other |
- Primary Purpose: Treatment
|
- Maximum tolerated dose of everolimus
- Toxicity
- Activation of PI3K/AKT and mTORC 1 in leukemic blasts
- Pharmacokinetics of everolimus
|
21 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00544999 |
CDR0000564068
IRLMS-GOELAMS-RAD001
INCA-RECF0476 |
|
September 2007 |
April 2010 |
|
October 16, 2007 |
September 17, 2013 |
|
- Hopital Cochin
Paris, France
|
|
| 86 |
NCT00509093 |
Unknown † |
Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy |
|
- Drug: imatinib mesylate
- Genetic: gene expression analysis
- Genetic: mutation analysis
- (and 3 more...)
|
Interventional
|
Phase 2 |
- Case Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival for patients less than 60 years of age
- Progression-free survival for patients 60 years of age and older
- Toxicity as measured by NCI CTC v. 3.0
- Correlation of c-kit expression with multidrug resistance gene expression (MDR1, MRP1, LRP, and BCRP) and AF1q expression
|
32 |
All |
18 Years and older (Adult, Older Adult) |
NCT00509093 |
CASE4906
P30CA043703
AUS259
NCI-2010-01198 |
|
December 2008 |
April 2013 |
|
July 31, 2007 |
November 1, 2016 |
|
- Roswell Park Cancer Institute
Buffalo, New York, United States - Duke University Medical Center
Durham, North Carolina, United States - University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States - Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
|
| 87 |
NCT00049179 |
Completed |
S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia |
|
- Drug: cytarabine
- Drug: gemtuzumab ozogamicin
|
Interventional
|
Phase 2 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
33 |
All |
18 Years and older (Adult, Older Adult) |
NCT00049179 |
S0117
U10CA032102 |
|
April 2003 |
December 2005 |
October 2010 |
January 27, 2003 |
March 6, 2015 |
|
- Alta Bates Comprehensive Cancer Center
Berkeley, California, United States - Mills-Peninsula Health Services
Burlingame, California, United States - Marin Cancer Institute at Marin General Hospital
Greenbrae, California, United States - (and 148 more...)
|
|
| 88 |
NCT00844441 |
Completed |
Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia |
- Leukemia
- Myelodysplastic Syndromes
|
- Other: medical chart review
- Other: questionnaire administration
- Procedure: quality-of-life assessment
|
Interventional
|
Not Applicable |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Health Services Research
|
- Death rate in patients discharged after completion of induction chemotherapy
- Rate of successful discharge of patients who meet medical discharge criteria
- Costs associated with outpatient vs inpatient treatment
- Medical resources used with outpatient vs inpatient treatment
|
96 |
All |
18 Years to 60 Years (Adult) |
NCT00844441 |
2300.00
P30CA015704
FHCRC-2300.00
IR 6845
CDR0000631997 |
|
December 2008 |
September 2010 |
March 2011 |
February 16, 2009 |
May 19, 2011 |
|
- Oregon Health and Science University
Portland, Oregon, United States - Fred Hutchinson Cancer Research Center
Seattle, Washington, United States - Clinical Cancer Research Center at University Hospital Basel
Basel, Switzerland
|
|
| 89 |
NCT00003405 |
Unknown † |
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia |
|
- Biological: recombinant interferon alfa
- Drug: amifostine trihydrate
- Drug: bromodeoxyuridine
- (and 5 more...)
|
Interventional
|
Phase 2 |
- Rush University Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
45 |
All |
up to 70 Years (Child, Adult, Older Adult) |
NCT00003405 |
CDR0000066413
RUSH-AML-9754
ALZA-RUSH-AML-9754
NCI-V98-1445 |
|
April 1998 |
|
|
May 24, 2004 |
February 9, 2009 |
|
- Cook County Hospital
Chicago, Illinois, United States - Rush Cancer Institute
Chicago, Illinois, United States - Angelo P. Creticos, M.D. Cancer Center
Chicago, Illinois, United States - Rush-Riverside Cancer Center
Kankakee, Illinois, United States
|
|
| 90 |
NCT00002658 |
Unknown † |
Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia |
|
- Biological: filgrastim
- Drug: amsacrine
- Drug: cyclophosphamide
- (and 11 more...)
|
Interventional
|
Phase 3 |
- Medical Research Council
- National Cancer Institute (NCI)
|
Other |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
2000 |
All |
15 Years and older (Child, Adult, Older Adult) |
NCT00002658 |
CDR0000064208
MRC-LEUK-AML12
EU-95001 |
|
January 1994 |
|
|
April 10, 2003 |
December 19, 2013 |
|
- University of Wales College of Medicine
Cardiff, Wales, United Kingdom
|
|
| 91 |
NCT00005795 |
Completed |
Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia |
|
|
Interventional
|
Phase 2 |
- Northwestern University
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
11 |
All |
16 Years and older (Child, Adult, Older Adult) |
NCT00005795 |
NCI 99H6
NU-99H6
NU-476-016
NCI-T99-0094 |
|
February 2000 |
July 2002 |
July 2002 |
February 16, 2004 |
June 11, 2012 |
|
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States
|
|
| 92 |
NCT00066794 |
Completed |
S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia |
|
- Biological: filgrastim
- Biological: sargramostim
- Drug: cyclosporine
- (and 2 more...)
|
Interventional
|
Phase 2 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
69 |
All |
56 Years and older (Adult, Older Adult) |
NCT00066794 |
S0301
U10CA032102 |
|
July 2004 |
February 2007 |
January 2010 |
August 7, 2003 |
March 6, 2015 |
|
- Mobile Infirmary Medical Center
Mobile, Alabama, United States - Arizona Cancer Center at University of Arizona Health Sciences Center
Tucson, Arizona, United States - Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
Orange, California, United States - (and 94 more...)
|
|
| 93 |
NCT00112554 |
Completed |
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia |
|
- Drug: cytarabine
- Drug: laromustine
- Other: placebo
|
Interventional
|
Phase 3 |
- Vion Pharmaceuticals
- National Cancer Institute (NCI)
|
Industry |
- Allocation: Randomized
- Masking: Double
- Primary Purpose: Treatment
|
- Overall response rate
- Time to tumor progression
- Duration of response
- (and 2 more...)
|
420 |
All |
18 Years and older (Adult, Older Adult) |
NCT00112554 |
CDR0000430677
VION-CLI-037 |
|
March 2005 |
March 2008 |
March 2008 |
June 3, 2005 |
November 6, 2013 |
|
- USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, United States - Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California, United States - Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
Orange, California, United States - (and 59 more...)
|
|
| 94 |
NCT00101153 |
Completed |
Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia |
|
- Drug: cytarabine
- Drug: daunorubicin hydrochloride
- Drug: tipifarnib
|
Interventional
|
Phase 1 |
- University Health Network, Toronto
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of tipifarnib when administered with cytarabine and daunorubicin
- Toxicity
- Pharmacokinetics
|
24 |
All |
56 Years and older (Adult, Older Adult) |
NCT00101153 |
PMH-PHL-026
CDR0000405840
NCI-6670 |
|
April 2007 |
March 2010 |
|
January 10, 2005 |
July 23, 2015 |
|
- McMaster Children's Hospital at Hamilton Health Sciences
Hamilton, Ontario, Canada - London Regional Cancer Program at London Health Sciences Centre
London, Ontario, Canada
|
|
| 95 |
NCT00963521 |
Completed |
Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission |
|
- Biological: therapeutic autologous dendritic cells
|
Interventional
|
Phase 1 |
- Institut Paoli-Calmettes
- National Cancer Institute (NCI)
|
Other |
- Allocation: Non-Randomized
- Primary Purpose: Treatment
|
- Adverse events at 6 months
|
10 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00963521 |
CDR0000626786
IPC-2006-011
INCA-RECF-0628
EUDRACT-2006-007093-29
IPC-LADC |
|
June 2008 |
May 2011 |
|
August 21, 2009 |
May 13, 2011 |
|
- Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes
Marseille, France
|
|
| 96 |
NCT00739388 |
Completed |
Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy |
|
|
Interventional
|
Phase 2 |
- Swiss Group for Clinical Cancer Research
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Best response (complete or partial response)
- Time to response
- Response duration
- (and 7 more...)
|
47 |
All |
18 Years and older (Adult, Older Adult) |
NCT00739388 |
SAKK 30/07
SWS-SAKK-30/07
CDR0000612029 |
|
July 2008 |
January 2010 |
November 2012 |
August 21, 2008 |
April 10, 2013 |
|
- Kantonspital Aarau
Aarau, Switzerland - Kantonsspital Baden
Baden, Switzerland - Universitaetsspital-Basel
Basel, Switzerland - (and 8 more...)
|
|
| 97 |
NCT00089050 |
Completed |
Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia |
|
- Drug: cyclosporine
- Drug: gemtuzumab ozogamicin
|
Interventional
|
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy in terms of complete remission rate
- Toxicity
- Pharmacokinetics
- Correlate clinical response to laboratory studies of drug susceptibility
|
|
All |
60 Years and older (Adult, Older Adult) |
NCT00089050 |
1820.00
FHCRC-1820.00
CDR0000378021 |
|
May 2004 |
|
March 2006 |
August 5, 2004 |
November 30, 2011 |
|
- Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
|
|
| 98 |
NCT00093483 |
Completed |
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia |
|
- Biological: filgrastim
- Drug: arsenic trioxide
- Drug: cytarabine
- Drug: idarubicin
|
Interventional
|
Phase 1 |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose and/or biologically effective dose or arsenic trioxide
|
61 |
All |
18 Years to 59 Years (Adult) |
NCT00093483 |
CDR0000387999
P30CA016056
RPCI-RP-0209 |
|
April 2002 |
November 2009 |
December 2009 |
October 8, 2004 |
January 13, 2014 |
|
- Roswell Park Cancer Institute
Buffalo, New York, United States
|
|
| 99 |
NCT00121303 |
Completed |
Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes |
- Leukemia
- Myelodysplastic Syndromes
|
- Drug: cytarabine
- Drug: daunorubicin hydrochloride
- Drug: gemtuzumab ozogamicin
|
Interventional
|
Phase 3 |
- Stichting Hemato-Oncologie voor Volwassenen Nederland
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event-free survival after induction therapy
- Disease-free survival after maintenance therapy
- Complete remission (CR) rate after induction therapy
- (and 5 more...)
|
600 |
All |
61 Years to 120 Years (Adult, Older Adult) |
NCT00121303 |
CDR0000433422
SAKK-AML-43
EU-20514
HOVON-AML-43 |
|
January 2005 |
January 2009 |
June 2016 |
July 21, 2005 |
September 20, 2016 |
|
- North Hampshire Hospital
Basingstoke, England, United Kingdom - Kent and Canterbury Hospital
Canterbury, England, United Kingdom - Medway Maritime Hospital
Gillingham Kent, England, United Kingdom - (and 3 more...)
|
|
| 100 |
NCT00534469 |
Active, not recruiting |
Busulfan, Etoposide, and Total-Body Irradiation Followed by Autologous Stem Cell Transplant and Aldesleukin in Treating Patients With Acute Myeloid Leukemia in First Remission |
|
- Biological: aldesleukin
- Biological: filgrastim
- Drug: busulfan
- (and 7 more...)
|
Interventional
|
Phase 2 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy of preparative therapy as measured by 2- and 5-year disease-free survival
- Toxicity of preparative therapy
- Feasibility of administration and ability to tolerate aldesleukin after transplantation
- Effect of cytogenetics, WBC at presentation, targeted busulfan dose, and number of courses of induction therapy required to achieve remission on possible prognostic factors for relapse, disease-free survival, and overall survival
|
50 |
All |
16 Years to 60 Years (Child, Adult) |
NCT00534469 |
99040
P30CA033572
CHNMC-99040
CDR0000564772 |
|
October 2000 |
January 2019 |
January 2019 |
September 24, 2007 |
February 9, 2018 |
|
|
|
Create an RSS feed from your search for:
Download the search results for: